GENSIGHT BIOLOGICS S.A. (EPA:SIGHT) | WebDisclosure

Basculer en Français

10964	Companies
239965	Keywords
168732	Articles
129105	Press releases

Headlines Articles Press releases GENSIGHT BIOLOGICS S.A.

Home
Companies
GENSIGHT BIOLOGICS S.A.

PRESS RELEASE

published on 09/23/2024 at 19:36, 1 year 11 months ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie ses résultats financiers du premier semestre 2024 avec une réduction des dépenses opérationnelles de 60% et l'extension de son horizon de trésorerie. Nouveau Directeur Administratif et Financier nommé

Résultats Financiers GenSight Biologics Directeur Administratif Et Financier Dépenses Opérationnelles Horizon De Trésorerie
BRIEF

published on 09/17/2024 at 14:45, 1 year 11 months ago

Goldman Sachs vend ses actions GENSIGHT BIOLOGICS S.A.

Euronext Paris Franchissement De Seuils Goldman Sachs Cession D'actions GenSight Biologics
BRIEF

published on 09/17/2024 at 14:45, 1 year 11 months ago

Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares

Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
PRESS RELEASE

published on 09/17/2024 at 14:40, 1 year 11 months ago

Franchissement de seuils
Déclaration de franchissement de seuils par The Goldman Sachs Group, Inc. concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris

Euronext Paris Déclaration The Goldman Sachs Group Franchissement De Seuils GenSight Biologics
BRIEF

published on 07/23/2024 at 07:35, 2 years 1 month ago

GenSight Biologics Reports Financial Position and Business Progress

Gene Therapy Financial Update GenSight Biologics LUMEVOQ Early Access Program
BRIEF

published on 07/23/2024 at 07:35, 2 years 1 month ago

GenSight Biologics présente sa situation financière et ses progrès commerciaux

Thérapie Génique Mise À Jour Financière Produits Biologiques GenSight LUMEVOQ Programme D'accès Anticipé
PRESS RELEASE

published on 07/23/2024 at 07:30, 2 years 1 month ago

Inside Information / News release on accounts, results
GenSight Biologics reports cash position of €6.9 million as of June 30, 2024, with potential over 100 vials available upon Q3 resumption of early access program. Company confirms sufficient working capital and successful blending step for LUMEVOQ drug product

Working Capital Business Update Cash Position GenSight Biologics LUMEVOQ Drug Product
PRESS RELEASE

published on 07/23/2024 at 07:30, 2 years 1 month ago

Informations privilégiées / Communiqué sur comptes, résultats
GenSight Biologics publie sa position de trésorerie au 30 juin 2024, et fait le point sur ses activités. La trésorerie s'élève à 6,9 millions d'euros, suffisante jusqu'au quatrième trimestre 2024

Trésorerie GenSight Biologics Thérapies Géniques Activités LUMEVOQ
BRIEF

published on 07/11/2024 at 07:35, 2 years 1 month ago

GenSight Biologics Launches Newsletter for Retail Investors

Financial Updates Gene Therapy Retail Investors LUMEVOQ® Optogenetics
BRIEF

published on 07/11/2024 at 07:35, 2 years 1 month ago

GenSight Biologics lance une newsletter destinée aux investisseurs particuliers

Investisseurs Particuliers Thérapie Génique LUMEVOQ® Optogénétique Mises À Jour Financières

Accesswire

Published on 09/10/2026 at 22:25, 5 hours 22 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 10 hours 1 minute ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 12 hours 27 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 12 hours 47 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 13 hours 10 minutes ago

Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 00:05, 3 hours 41 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 3 hours 46 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 5 hours 7 minutes ago

EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 5 hours 36 minutes ago

flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 5 hours 40 minutes ago

EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board

Les Echos

Published on 09/10/2026 at 19:30, 8 hours 17 minutes ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 8 hours 17 minutes ago

Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 9 hours 37 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 10 hours 2 minutes ago

COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 10 hours 4 minutes ago

Déclaration d'actions et de droits de vote au 31.08.2026

View all LES ECHOS COMFI WIRE